Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
Lorenzo Antonuzzo, Hidenori Takahashi, Joon Oh Park, Aumkhae Sookprasert, Roopinder Gillmore, Sheng-Shun Yang, Juan Cundom, Mila Petrova, Gina Vaccaro, Marielle Holmblad, Magdalena Żotkiewicz, Julie Wang, Nana Rokutanda, Do-Youn Oh
Oncologist 30(7) oyaf148
摘要
摘要
INTRODUCTION: We assessed immune-mediated adverse events (imAEs) in the TOPAZ-1 (NCT03875235) study of durvalumab plus gemcitabine and cisplatin (GemCis) in advanced biliary tract cancer (aBTC). METHODS: Participants were randomized 1:1 to durvalumab (1500 mg) or placebo, plus GemCis (gemcitabine [1000 mg/m2] and cisplatin [25 mg/m2]) intravenously, followed by durvalumab (1500 mg) or placebo Q4W. We assessed imAE incidence, time to onset (TTO), and association with overall survival (OS). RESULTS: In durvalumab (n = 338) versus placebo (n = 342), imAEs were reported in 13.9% versus 4.7% of participants, with median TTO of 127.0 versus 86.5 days, respectively. OS HR for durvalumab versus placebo in participants with imAEs was 0.59 (95% CI, 0.30-1.23) and was 0.83 (95% CI, 0.70-1.00) in participants without imAEs. CONCLUSIONS: Durvalumab demonstrated an OS benefit versus placebo in aBTC, irrespective of imAEs, which were mostly low grade and manageable. The results in these subgroups were consistent with the overall primary analysis. TRIAL REGISTRATION: ClinicalTrials.gov NCT03875235.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(1,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。